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Objective. To compare pregnancy rate after controlled ovarian hyperstimulation and intrauterine insemination (COH-IUI) with no
treatment in patients with endometriosis-associated infertility treated with laparoscopy. Design. A clinical cohort study. Setting.
University-level tertiary care center. Patients. 238 women with various stages of endometriosis after laparoscopic treatment.
Interventions. Either COH-IUI or follow-up for 12 months.Main Outcome Measures. The primary outcome measures were clinical
pregnancy and live birth rate. Predictive factors evaluated were female age, maternal BMI, and duration of infertility. Results. The
pregnancy rate attained after the integrated laparoscopy–COH-IUI approach was 53.4%, while it was significantly lower (38.5%)
in the control group. Similarly, a significant difference was observed in live births (48.3% versus 34.2%). Patients with severe
endometriosis were less likely to achieve pregnancy (38%) and live birth (35%) than their counterparts with milder forms (57% and
53%). Conclusions. In patients with endometriosis-based infertility, surgery followed by COH-IUI is more effective than surgery
alone.
1. Introduction
Endometriosis, the leading cause of infertility, has a preva-
lence of 0.5–5% in fertile women and 25–40% in infertile
women [1–3]. Although a broad spectrum of therapeutic
options is available, evidence-based management of infertil-
ity associated with endometriosis is still disputed [3–5].
Studies have provided conflicting results on surgery and
endometriosis. Although the majority of reports have indi-
cated that reparative surgery improves the rate of pregnancy
significantly, further research is needed on the efficacy of
surgery in endometriosis [1, 6]. Marcoux et al. [7] reported
that operative laparoscopy provides a significantly elevated
monthly fecundity rate compared to diagnostic laparoscopy
in endometriosis, while Parazzini et al. [8] found no signif-
icant improvement in the 12-month cumulative pregnancy
rates in stage I-II endometriosis. Women with advanced
endometriosis have a cumulative pregnancy rate of 44% after
12 months and 57.5% after 24 months, which is significantly
more favorable for stage III endometriosis patients than for
those with stage IV following surgery [9].
A combination of controlled ovarian hyperstimulation
(COH) with intrauterine insemination (IUI) has been eval-
uated for the treatment of infertility in surgically corrected
endometriosis [3, 5, 10], though the success of COH-IUI is
lower in endometriosis than in other types of infertility [5, 11].
COH-IUI after the surgical removal of endometrial deposits
improves the success rate less than in vitro fertilization (IVF)
[1, 3, 6].
The effect on pregnancy odds of COH-IUI after a combi-
nation of laparoscopic resection/ablation of the endometri-
otic lesions is little documented with conflicting results
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[12–15]. The aim of our present study was therefore to assess
whether COH-IUI has a significant effect on pregnancy
rate (PR), cumulative pregnancy rate (CPR), and live birth
rate (LBR) in infertile patients with endometriosis after
laparoscopic surgery.
2. Materials and Methods
This prospective clinical cohort study was conducted at the
Department of Obstetrics and Gynecology, University of
Szeged, from January 2002 to December 2008. All infertile
couples who presented at our infertility ward participated in
a complete investigation related to patient history, hysteros-
alpingogram, serum endocrine profile in the follicular phase,
midluteal progesterone concentrations, and sperm analysis of
the male partner.
2.1. Inclusion and Exclusion Criteria. Eligibility criteria were
as follows: the couple not conceiving after at least 1 year
of unprotected intercourse; the women being younger than
40; confirmation of an ovulatory cycle by midluteal serum
progesterone level; symptoms suggestive of endometriosis
(severe dysmenorrhea; deep dyspareunia; chronic pelvic
pain; ovulation pain; perimenstrual bowel- or bladder-
associated symptoms with or without abnormal bleed-
ing; and chronic fatigue); clinical signs (pelvic tender-
ness, a fixed (retroverted) uterus, tender uterosacral liga-
ments, or enlarged ovaries); incremental sonographic find-
ing (endometrioma(s)); and a normal spermiogram of the
partner according to the World Health Organization criteria
(sperm concentration at least 20 million/mL and 50% pro-
gressive motile spermatozoa within 1 h of ejaculation) [16].
Couples who presented with other gynecological pathologies
or coexisting causes of infertility besides endometriosis were
excluded.Womenwith additional obvious causes of infertility
such as any abnormality in anatomy, tubal factor, ovulatory
dysfunction, and polycystic ovarian syndrome were also
excluded from the study. Previous COH-IUI treatment or
steroid therapy and any condition affecting ovarian function
or blood-clotting disturbance that would exclude patients
from COH-IUI treatment (early menopause and ovarian
malignancy) also gained ground as exclusion criteria.
2.2. Patient Recruitment. After baseline registration, 382
patients were approached for potential participation, and
68 women declined to participate. In some patients with
endometriosis, surgerymay have been indicated to treat pain.
Women were excluded at this stage if they were medically
unfit for laparoscopy due to other diseases (𝑛 = 1) or
previous or current gynecological malignity (𝑛 = 1).
Another exclusion criterion was an inability to communicate
in Hungarian (𝑛 = 1). The participants were informed of
the study in detail and signed their informed consent to
participation.
All eligible participants (𝑛 = 311) were referred for
day-care operative laparoscopy for removal of endometriotic
lesions and adhesiolysis when necessary. At this stage, 47
participants were excluded as endometriotic lesions were not
found in the abdominal cavity during surgery. 26 women
were excluded because chromopertubation with methylene
blue dye revealed tubal patency as a cause of infertility besides
endometriosis.
In the remaining 238 cases, various stages of endometrio-
sis were identified by direct visualization, in accordance with
the revised American Society for Reproductive Medicine
classification [17]: 218 patients underwent laparoscopic
surgery and 20 patients were managed by laparotomy. Salp-
ingectomy was not performed. In 98 patients, an ovarian
endometrioma was removed, and cystectomy was associated
with adhesiolysis in 68 cases. In 198 patients, peritoneal
implants were electrocoagulated with bipolar forceps. In all
the patients, biopsy specimens were taken during surgeries,
and diagnosis was confirmed by histopathologic examina-
tion.
Current demographic data and clinical characteristics
were recorded after operation with the exception of the
duration of the menstrual cycle and infertility, which were
registered at the initial presentation before surgery. This was
followed by allocation of the participants into a case group
(COH-IUI intervention) or an equally large follow-up group
(observation without treatment). Nonrandom allocation was
based on age, BMI, and stage of endometriosis in order to
obtain two satisfactorily comparable matched study groups.
Both study groups underwent the same surgery protocol
for endometriosis. Excision of endometriotic lesions was
performed in 118 cases, cystectomy and adhesiolysis were
performed in 49 cases, and 98 patients underwent electro-
coagulation of the endometriotic deposits in the COH-IUI
treatment group, while 120 patients underwent resection, 49
received cystectomy with or without adhesyolysis, and 100
were electrocoagulated in the expectant management group.
Surgery was performed by the same authors in both groups
(Attila Keresztu´ri, Jo´zsef Daru, Ja´nos Szo¨llo˝si, and Sa´ndor
Kolosza´r). Figure 1 contains a flow chart for the study.
2.3. ControlledOvarianHyperstimulation, SemenPreparation,
and IUI. In the treatment group, COHwas started according
to the monofollicular protocol and was initiated in the
first menstrual cycle after the operation. The patients were
given clomiphene citrate (CC) 100mg/day (Clostilbegyt; Egis,
Hungary) between days 3 and 7 of the menstrual cycle. From
day 5 one ampoule Merional (IBSA Pharma, Slovakia, 75 IU
highly purified human menopausal gonadotropin (hMG)
containing follicle-stimulating hormone (FSH) with luteiniz-
ing hormone (LH)) was administered intramuscularly every
other day. When there was no sonographic evidence of ovar-
ian follicular activity and serum estradiol was <60 pg/mL,
the dose of Merional was doubled every other day. On day
5 or 6 of the stimulation, a transvaginal ultrasound (TVUS)
examination was carried out. If the size of the dominant
follicle and/or the thickness of the endometrium did not
reach the required size, the administration of Merional
was continued, with daily TVUS examination. When the
dominant follicle reached ≥17mm and the endometrium
was thicker than 9mm (consisting of 3 layers), 10,000 IU
human chorionic gonadotropin (hCG; Choragon, Ferring)
was given for luteinization after a determination of serum
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Figure 1: Study flow chart.
estradiol level. Whenever a risk of ovarian hyperstimula-
tion syndrome (OHSS) was suspected (e.g., >10 follicles,
>2 dominant follicles, ovary size > 10 cm, or a serum E2
level > 6000 pmol/L), luteinization was not carried out and
cycles with premature luteinization (progesterone levels >
1 ng/mL on the day of hCG) were also ruled out. Patients
that had undergone COH but had not been inseminated were
excluded from the study. Standard protocols were used for
insemination, which are detailed in a previous study [18]. In
brief, insemination involved extraction of the concentration
of sperm from the homogenized semen. Ejaculates, obtained
by masturbation, were prepared for IUI. The sperm was
washed and enriched by means of swim-up technology.
When the concentration reached the 40×106/mL value, 3mL
of washing fluid (Spermfit, Biomedical) was added to 1mL of
ejaculate. 400 g of themixture was centrifuged for 10minutes,
and the supernatant was drawn off.
Double IUI procedures were performed 36 hours after
hCG administration and on the subsequent day. All IUI
procedures were performed by the same four authors (Attila
Keresztu´ri, Jo´zsef Daru, Ja´nos Szo¨llo˝si, and Sa´ndor Kolosza´r).
To achieve the best possible effect in the IUI group, inter-
course was forbidden 5 days before the procedure and for
the rest of the cycle afterwards. The luteal phase was not
supported by any medication.
2.4. Patient Follow-Up. A serum hCG test was performed
to confirm pregnancy at the time of the first expected
menstrual period. Clinical pregnancy was diagnosed 2 weeks
after a positive test by ultrasound, indicating the presence
of an intrauterine gestational sac with a fetal echo. COH-
IUI treatment continued for a maximum of 6 cycles up to
successful pregnancy, with a no-treatment interval of 1-2
months interposed, which is acceptably effective [12].
The follow-up period lasted for 12 months from the
surgery in both study groups. The patients in the follow-up
group were referred for COH-IUI, while the patients who
had undergone insemination and did not achieve pregnancy
after the follow-up period were referred for IVF and embryo
transfer (IVF-ET). Our primary end point was pregnancy.
Secondary end points were overall cycle fecundity and live
birth. Miscarriage was defined as nonvital pregnancy or
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Table 1: Baseline characteristics of participants in the COH-IUI group (𝑛 = 116) and the control group (𝑛 = 117) at the Department of
Obstetrics and Gynecology, University of Szeged, from January 2002 to December 2008.
Treatment group
(COH-IUI) (𝑛 = 116) Control group (𝑛 = 117) 𝑝 value OR (95% CI)
Age (in years) (mean ± S.D.) 33.5 ± 4.2 32.9 ± 4.4 NS
Duration of menstrual cycle (days) (mean ± S.D.) 27.2 ± 3.4 29.3 ± 6.2 <0.05
Endometriosis
Stage I or II 48 (41.4%) 50 (43.7%) NS 0.95 (0.56–1.60)
Stage III or IV 68 (58.6%) 67 (57.3%)
Body weight (kg) (mean ± S.D.) 65.2 ± 7.3 64.0 ± 9.0 NS
Body mass index (kg/m2) (mean ± S.D.) 22.2 ± 1.9 21.9 ± 2.1 NS
Duration of infertility (years) (mean ± S.D.) 3.1 ± 2.1 2.9 ± 1.8 NS
Sperm parameters of partner
Sperm concentration (×106/mL) 79.9 ± 11.0 77.2 ± 13.0 NS
Range 21–139 16–153 NS
Sperm motility (%) 72.9 ± 4.0 77.1 ± 2.4 NS
Range 67–83 64–81 NS
Sperm morphology (%) 57.8 ± 5.4 53.9 ± 3.7 NS
Range 36–75 31–75 NS
COH-IUI: controlled ovarian hyperstimulation and intrauterine insemination; S.D.: standard deviation; OR: odds ratio, 95% CI: 95% confidence interval; NS:
statistically not significant.
the loss of a previously visible pregnancy, while an ectopic
pregnancy was a conception outside the uterine cavity.
2.5. Statistical Analyses. Statistical analysis was performed
with the 𝑡-test and chi-square test as appropriate. The data
were analyzed with the Statistical Package for the Social
Sciences (SPSS) for Windows (version 15.0; SPSS, Inc.,
Chicago, IL, USA). For sample size calculation, we used
StatMate 2 for Windows software. Assuming a PR of 11%
[13] following COH-IUI, it was calculated that 220 cycles
would be required to detect an absolute 5% increase with
an alpha error level of 0.05 and a beta error level of 0.2.
The crude probabilities of pregnancy and live birth rates
were calculatedwith the starting point of surgery. Cumulative
ongoing clinical pregnancy rates are illustrated for both
groups. To test between-group differences, theKruskal-Wallis
analysis of variance was used. Statistical significance was
set at 𝑝 < 0.05 and all statistical tests were 2-sided. The
study protocol was approved by the Clinical Research Ethics
Committee at the University of Szeged.
3. Results
Out of the 238women eligible for inclusion, 119were allocated
into the treatment group and 119 into the follow-up group.
One participant in the control group was lost to follow-
up, and 3 women did not take part in hormonal induction
because of the development of mild OHSS (Figure 1). The
baseline values were used as follow-up values in the statistical
analysis.
There were no significant differences between the two
groups concerning age, duration of infertility, body weight,
BMI, distribution of endometriosis stages, and sperm
Table 2: Cycle characteristics of the COH-IUI group (𝑛 = 281) at
the Department of Obstetrics andGynecology, University of Szeged,
from January 2002 to December 2008.
Hormone profile
Day 3 FSH (mIU/mL) 5.34 ± 2.1
Day 3 LH (mIU/mL) 4.89 ± 3.9
Day 3 E2 (pmol/L) 47.29 ± 40.0
hCG day E2 (pmol/L) 642.8 ± 312.2
hCG day P (ng/mL) 0.39 ± 0.19
hCG day endometrial thickness (mm) 12.11 ± 2.00
Day of hCG administration 9.12 ± 3.01
COH-IUI: controlled ovarian hyperstimulation and intrauterine insemi-
nation, expressed as mean ± standard deviation, FSH: follicle-stimulating
hormone, LH: luteinizing hormone, E2: estradiol, and P: progesterone.
parameters. Endometriosis was found in stage I or II in 100
patients (42.0%) and in stage III or IV in 138 patients (58.0%).
The patients were between 23 and 39 years of age (means:
33.5 years versus 32.9 years in the case and follow-up groups,
resp.), and the lengths of ongoing infertility were 3.1 years and
2.9 years in the case and follow-up groups, respectively. Both
the body weight (means: 65.2 kg versus 64.0 kg, in the case
and follow-up groups, resp.) and the BMI (means: 22.2 kg/m2
versus 21.9 kg/m2, in the case and follow-up groups, resp.)
were similar in the two groups.The duration of themenstrual
cycle ranged from 24 to 39 days in both groups (means: 27.2
days versus 29.3 days, in the case and follow-up groups, resp.).
Sperm qualities have also been tabulated (Table 1).
Table 2 provides an overview of the clinical characteristics
of the COH-IUI cycles. Both the hormone profiles on day
3 and the hormone profiles and endometrium thicknesses
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Table 3: Pregnancy characteristics of participants of the COH-IUI group (𝑛 = 116) and the control group (𝑛 = 117) at the Department of
Obstetrics and Gynecology, University of Szeged, from January 2002 to December 2008.
Treatment group (COH-IUI)
(𝑛 = 116) Control group (𝑛 = 117) 𝑝 value OR (95% CI)
CPR (per protocol) 62/116 53.4 45/117 38.5 0.026 1.84 (1.09–3.09)
CPR (endometriosis stages I-II) 31/48 64.6 25/50 50.0 NS 1.82 (0.81–4.10)
CPR (endometriosis stages III-IV) 31/68 45.6 20/67 29.9 NS 1.97 (0.97–4.00)
Miscarriage 2/62 3.2 3/45 6.7 NS 0.47 (0.08–2.92)
Ectopic pregnancy 2/62 3.2 1/45 2.2 NS 1.47 (0.13–16.7)
LBR per protocol 58/116 48.3 41/117 34.2 0.024 1.85 (1.09–3.14)
LBR (endometriosis stages I-II) 30/48 62.5 22/50 44.0 NS 2.12 (0.94–4.76)
LBR (endometriosis stages III-IV) 28/68 41.2 19/67 28.4 NS 1.77 (0.86–3.63)
Multiple pregnancy 4/62 6.5 0/45 0 NS 0.94 (0.88–1.00)
COH-IUI: controlled ovarian hyperstimulation and intrauterine insemination; CPR: cumulative pregnancy rate; LBR: live birth rate; NS: statistically not
significant.
on the day of hCG administration were appropriate. The
IUI protocol was cancelled in only 3 cases due to ovulation
induction, with CC+hMG causing mild OHSS.
Table 3 relates to the PR and LBR in the two groups. The
116 treated cases underwent 281 cycles of COH-IUI, with a
mean of 2.42 cycles per patient. 62 pregnancies occurred, thus
representing an overall cycle fecundity of 22.1% and a CPR of
53.4%.
Forty-five pregnancies were recorded among the 117
control participants. The CPR of 38.5% was significantly
lower than that among the COH-IUI cases (53.4%).The CPR
in the first 6monthswas 27.3%,with a further increase of 11.1%
in the following 6 months, which is significantly different
(𝑝 < 0.05).
The CPR in stages I-II and stages III-IV in the COH-
IUI group were 64.6% and 45.6%, respectively. The corre-
sponding rates in stages I-II and stages III-IV in the follow-up
groupwere 50.0% and 29.9%, respectively; the differences did
not reach the level of significance. The CPR was significantly
higher among those in stages I-II (64.6%) than in those
with endometriosis stages III-IV (45.6%) (𝑝 = 0.005). The
Kruskal-Wallis test revealed a significant difference (𝑝 =
0.003) in the cumulative ongoing pregnancy rates between
the two groups (Figure 2), indicating that the COH-IUI inter-
vention significantly increased the likelihood of pregnancy
relative to that in the follow-up group during the one-year
study period.
Among the total of 107 pregnancies, 5 spontaneous
abortions (4.7%) and 3 ectopic pregnancies (2.8%) were
recorded, and there was a higher LBR in the COH-IUI
group (48.3%) than in the follow-up group (34.2%). Four
participants had twins after COH-IUI (6.5%). A previous
diagnosis of endometriosis at stage I or II was associated with
a significantly higher LBR (57.1%) than that for stages III-IV
(37.8%) (𝑝 = 0.005).
As expected, patients with endometriosis tended to have
lower odds of pregnancy as the age increased (𝑝 = 0.04,
𝑟 = 0.62) and at higher BMI (𝑝 = 0.001, 𝑟 = 0.73).
The PR was significantly lower among women over 35 years
of age than among younger women (24.6% versus 53.8%).
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Figure 2: Cumulative ongoing clinical pregnancy rates in the two
study groups at the Department of Obstetrics and Gynecology,
University of Szeged, from January 2002 to December 2008.
The PR per cycle in women over 35 (12.3%) was similarly
significantly lower than in younger women (23.1%). To our
surprise, the duration of infertility was not a significant
predisposing factor for achieving pregnancy in endometriosis
(𝑟 = 0.21).Therewas no recognizable association between the
sperm parameters or endometrium thickness and the success
of COH-IUI.
4. Discussion
Our most striking finding is that the probability of concep-
tion and a resultant live birth is significantly higher after
integrated laparoscopy–COH-IUI management than that of
spontaneous pregnancy and live birth after surgical treatment
only in women with endometriosis and particularly among
those with a mild form.
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Twelve-month cumulative pregnancy rates in stages I-II
were 50% for spontaneous attempts and 64.6% for COH-IUI
and in stages III-IV were 29.9% for spontaneous attempts and
45.6% for COH-IUI in our study. Although these differences
are not significant, they suggest considerably elevated preg-
nancy odds for COH-IUI compared to expectant manage-
ment. Cumulative pregnancy rates for COH-IUI in stages I-
II were significantly higher than in stages III-IV. Moreover,
live birth rates are slightly more frequent following a COH-
IUI procedure than in the group with spontaneous attempts
during 12 months.
Based on our results, COH-IUI should therefore be
offered to patients as a treatment option after laparoscopy,
particularly in moderate-to-severe forms, in agreement with
other studies [19, 20] and in contrast with one study [15].
Gandhi et al. [15] stated that stimulation with gonadotropins
is superior to stimulation with CC.
The latest retrospective report has demonstrated
poorer results on the efficacy of postoperative COH-IUI in
endometriosis, where the cumulative pregnancy rate after
6 COH-IUI (12 months) was 45% and 42% in controls in
mild-to-moderate endometriosis and the corresponding
rates were 10%–20% in advanced endometriosis, respectively
[15]. These rates are somehow lower than our results, but
there were far fewer participants included in the study and
the results reported were mixed for COH only, IUI only,
and COH-IUI cycles. Furthermore, they mostly used only
CC/Letrozole as COH agents [15] and not CC/hMG, as we
did.
Endometriosis has the lowest likelihood of fertility among
infertile patients [5, 11], with the odds of fecundity in
untreated women with endometriosis ranging from 0.02 to
0.1% [21]. This is enhanced after laparoscopic treatment from
30–37% at 2 years [7, 22] to 60% at 3 years [23]. Our
results revealed that COH-IUI results in a PR per cycle
of 22.1% after surgery. A minor limitation of our study is
that a matched control study was performed rather than
a randomized controlled trial (RCT). No RCT has been
published on the effectiveness of COH-IUI treatment after
surgery. Furthermore, COH-IUI is an advocated treatment
option for minimal and mild endometriosis [3, 6], and there
is a relative dearth of reports on the fecundity rate of COH-
IUI after reparative surgery of moderate and advanced stages
[1].
It has been concluded by others [12, 13] that a course of
COH-IUI up to 3 cycles is the optimal regimen. However,
our data suggest that 6 cycles appear beneficial. Furthermore,
there is no consensus in the literature on prioritizing single or
double IUI; the reported trend is for better results with double
COH-IUI [24], and the double procedure was therefore
applied in our routine.
Although the power of our study is not sufficient for a
comparison of the endometriosis subgroups, it seems that
women with more severe endometriosis were less likely to
have a successful reproductive outcome from COH-IUI than
those with mild disease. In the cumulative pregnancy curve
(Figure 2), it should be noted that the immediate postoper-
ative period was particularly favorable for conception in the
follow-up group. Moreover, as expected, a significant inverse
correlation was observed between disease severity and spon-
taneous pregnancy. In contrast, among women with stage
I or II endometriosis, the fecundity rate remained elevated
throughout the first year after surgery, whereas patients with
endometriosis at advanced stages had a significantly higher
fecundity in the first half year than in the second (𝑝 <
0.05).This suggests that, after combined therapy with surgery
treatment, the ideal waiting time would be half a year for
endometriosis in an advanced stage.This contrasts somewhat
with a proposal made following a recent meta-analysis
where 6–18monthswas suggested for spontaneous pregnancy
[1].
Our results revealed that stimulation with CC/hMG
resulted in a higher CPR than that with CC [15]. As in the
literature [5], the rate of twins (6.5%) and the frequency of
OHSS (2.5%) were satisfactorily low in our sample, which is
characteristic of endometriosis.
Several reports have described factors leading to poor
prognosis of COH-IUI as an infertility diagnosis [1, 3–
6, 11], in accordance with our results, including advancing
female age [1, 3, 4, 6, 11], a higher BMI [11, 25], and
endometriosis itself. Inconsistent with previous reports, a
longer infertility period [5, 11, 25] did not decrease the
likelihood of conception in our dataset, and the success
of COH-IUI was not influenced by endometrial thickness
above 9mm [25], a poorer sperm motility [11, 25], or a
lower content of inseminated sperm [11, 25] in our patients
with endometriosis. Moreover, our study comprised selected
patients with infertility, while most of the previous reports
included women without infertility before the laparoscopy,
which could bias the studies.
Thedata on surgical treatment of advanced endometriosis
with the aim of pregnancy are inconclusive [1, 7, 9, 22, 23,
26]. In cases of ovarian endometrioma-associated infertility,
surgery must be considered as the first-line treatment, what-
ever the subsequent proposed technique [22]. Some studies
propose assisted reproductive technologies without prior
surgery in stage IV endometriosis, due to excessive ovarian
damage during surgery leading to a decreased ovarian reserve
and response and thus resulting in a lower PR [27, 28]. It
has also been established that the CPR is significantly higher
for IVF-ET than for COH-IUI (73% versus 41%), especially
in stage IV and in women over 38 years of age [13] when
prior surgery has not occurred. If COH-IUI is attempted, it
should not exceed three to four cycles, and a COH-IUI failure
beforehand does not affect the IVF-ET outcome adversely
[13].
A recent study [14] suggests that ovarian stimulation and
IUI in women with surgically treated mild endometriosis is
as effective as in unexplained infertility. Werbrouck et al. [14]
reported a PR per cycle of 21% in minimal endometriosis
and of 18.9% in the mild stage, following COH-IUI shortly
after laparoscopic excision, which is comparable to our result
(22.1%). However, the cumulative LBR within 4 cycles of
COH-IUI was higher in women with minimal or mild
endometriosis (70.2% and 68.2%) [14] as compared with our
results (62.5% versus 44.5%), but only 4 double IUI cycles
were used in regimen and only patients with no previous
pregnancy were included in our study.
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5. Conclusions
In conclusion, after operative treatment of any type of
endometriosis, COH-IUI is indicated as a second-line treat-
ment even in cases of advanced maternal age. The combined
approach of surgery and IUI may offer improved chances of
pregnancy for infertile women with endometriosis. Patients
should be advised to begin attempting to conceive naturally
soon after laparoscopic surgery. When pregnancy does not
occur within 6 months, they should move on to COH-IUI.
Further research is warranted to provide further evidence for
the role of postoperative COH-IUI in fertility treatment for
endometriosis.
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